-
Spurs boss De Zerbi targets one more big signing before window shuts
-
Meta's teen safety deal runs into an unsolved problem: proving age
-
Fed chair Warsh flags high US inflation as 'concerning'
-
Windmills of change: Dutch raise mill in rare operation
-
Same Election Question, Two Different Odds: Predictions.io Launches Free Cross-Venue Comparison Tools
-
Netanyahu party in uproar as far-right refuses pleas to unite
-
Man Utd new signing Baleba sidelined for three weeks
-
Stocks advance with all eyes on Fed chair's speech
-
Juve's Yildiz to miss 'several months' with foot injury
-
War criminal Ratko Mladic's death lays bare Bosnia's wounds
-
Celine Dion arrives in France ahead of sold-out comeback dates
-
Thieves buy tickets before plundering necklace from Vienna museum
-
All-round Tongue stars for England in second Test against Pakistan
-
Swiss nuclear plant fully back online after heatwaves
-
UEFA's legal move 'massive escalation' in bitter Infantino feud
-
Bournemouth, Sunderland to face AC Milan in Europa League
-
MEXC Launches Earn Plus With Limited-Time Event Offering Up to 800% APR Booster
-
Once a legend, humpback whales make comeback in Brazil
-
Norway's new King Haakon VIII, popular face of shaken monarchy
-
'Ran for our lives': Tales of survival from Nepal-China disaster
-
Stocks rise ahead of Fed chair's policy speech
-
Bombay High Court Questions Police Probe in Disha Salian Death Case
-
Norway's new King Haakon VII, popular face of shaken monarchy
-
Orthopaedician Dr Akhil Kulshreshtha Shares 5 Tips for Bone and Joint Health
-
Last-wicket duo take England to 290 all out in 2nd Test against Pakistan
-
All eyes on Warsh as Fed chair kicks off key central banking meeting
-
MPSC Drug Inspector Exam Leak: Rutuja Patil Allegedly Paid Rs 50 Lakh for Leaked Paper
-
ONE App Launches AI Agent and Custom GPT to Enhance Digital Banking
-
Japan spent record $96 bn in yen interventions: ministry
-
Indonesia escalates battle against fires, putrid haze
-
Nepal-China floods disaster: Latest developments
-
Germany could miss climate goal in 2026 for first time: think tank
-
Duplantis needs A-game to fend off Karalis pressure
-
New flood risks impede Nepal, Tibet rescue
-
Architect Minenhle Makhanya Ordered to Repay R147 Million for Nkandla Upgrades
-
Kolbe back as Springboks change two for All Blacks Test
-
Iran says still open to diplomacy as war with US hits six months
-
Europe's monarchs, world leaders mourn Norway's King Harald
-
20,000 Salmon Return to Klamath River Following Dam Removal, Yet Recovery Faces Ongoing Challenges
-
Jamie Vardy channel to broadcast Bundesliga games
-
King Harald, 'symbol' of Norway, dead at 89
-
STARCARES Completes Basketball Court Revamp in the Philippines, Benefiting Nearly 20,000 People
-
Norway's new King Haakon, popular face of shaken monarchy
-
Norway's new Queen Mette-Marit, a fairytale beset by woe
-
Most stocks rise as attention turns to Warsh speech
-
Nepal orders rescuers to safety as overflow brings new flood risks
-
Japanese rugby U-turns on limits on naturalised players
-
Norway's King Harald V, unifying force who weathered family storms
-
Norway's King Harald dead at 89
-
Australia's McKeown vows to reclaim backstroke world records
Rancho BioSciences Appoints Chris O'Brien as CEO to Deliver AI-Ready Data Solutions for Faster, More Reliable R&D
Veteran life sciences leader to drive enterprise growth and expand adoption of AI-ready data solutions across pharma and biotech
SAN DIEGO, CA / ACCESS Newswire / March 25, 2026 / Rancho BioSciences today announced the appointment of Chris O'Brien as Chief Executive Officer. O'Brien will lead the company's next phase of growth as Rancho expands adoption of its AI-ready data solutions across pharmaceutical, biotechnology, and research organizations.
Rancho BioSciences delivers AI-ready data solutions that transform fragmented biomedical data into standardized, reusable assets for AI, analytics, and machine learning. As life sciences organizations continue investing in AI and advanced analytics, preparing inconsistent and siloed data remains a major bottleneck-often slowing analysis and limiting reuse across programs. Rancho addresses this by standardizing and harmonizing complex data so it can be used immediately and consistently across the R&D lifecycle.
O'Brien brings more than 20 years of leadership experience building and scaling organizations across the life sciences and research services ecosystem. Most recently, he served as Chief Executive Officer of Biorasi, where he led global clinical research operations supporting emerging biotech and pharmaceutical companies. Earlier, he served as President and Chief Operating Officer of Decision Resources Group and founded Linchpin Partnerships, advising organizations on growth strategy and strategic partnerships. He holds an MBA from the Tuck School of Business at Dartmouth and a BA from Middlebury College.
As CEO, O'Brien will focus on accelerating the expansion of Rancho's portfolio of data and AI-enabled solutions, strengthening operational rigor across the organization, and driving growth across enterprise accounts. A key priority will be scaling Rancho's platform capabilities to support larger, more strategic engagements, while improving efficiency, predictability, and speed across both the commercial and delivery lifecycle.
"Chris brings the leadership and operational experience we need to grow Rancho's impact in a rapidly evolving market," said Julie Bryant, founder and Chief Strategy Officer of Rancho BioSciences. "Our clients are no longer asking for one-off data projects-they need AI data strategy and execution partners who can deliver repeatable, future-proof solutions that can be applied across programs and therapeutic areas. Chris understands how to scale that kind of delivery while maintaining the scientific rigor our clients expect."
"I'm excited to join Rancho Biosciences at this pivotal moment," said Chris O'Brien. "The increasing complexity and volume of scientific data and the rapid adoption of AI create a clear need for trusted partners who can deliver structured, high-quality data and actionable insights at enterprise scale. Julie Bryant and Rancho have built a strong foundation, and I look forward to working with the team to expand our impact, deepen client partnerships, drive sustained growth and help bring life-saving medicines to patients in need."
"Chris brings the leadership and execution focus required to scale Rancho into its next phase," said Ray Hill, Operating Partner at Arsenal Capital Partners. "His experience building high-performing teams and driving commercial discipline, combined with a deep understanding of the life sciences R&D ecosystem, will be instrumental in advancing Rancho's growth strategy and delivering long-term value to clients."
Chris's appointment reinforces Rancho's strategic focus on building a scaled, science-led data and AI platform that enables life sciences organizations to improve decision-making and increase R&D productivity. The company will continue to invest in its core capabilities, data assets, and strategic alliances to support long-term, durable growth.
About Rancho BioSciences
Rancho BioSciences delivers AI-ready data solutions that enable life sciences organizations to standardize, integrate, and reuse complex biomedical data across the R&D lifecycle. With more than 150 scientists, data engineers, and bioinformatics specialists, Rancho supports faster, more reliable analytics and AI-driven decision-making across discovery, translational research, and clinical development. The company's expertise spans data engineering, scientific curation, bioinformatics, data science, and strategic data initiatives. Rancho is driven by its mission of Saving Lives Through Data.
Contact Information
Jonathan Amir (VP, Marketing): [email protected]
SOURCE: Rancho BioSciences, LLC
View the original press release on ACCESS Newswire
O.Salvador--PC